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Abstract
Background: Previously, we identified a major myeloid-derived proinflammatory subpopulation of human blood dendritic
cells which we termed slanDCs (e.g. Scha¨kel et al. (2006) Immunity 24, 767–777). The slan epitope is an O-linked sugar
modification (6-sulfo LacNAc, slan) of P-selectin glycoprotein ligand-1 (PSGL-1). As slanDCs can induce neoantigen-specific
CD4+ T cells and tumor-reactive CD8+ cytotoxic T cells, they appear as promising targets for an in vivo delivery of antigens for
vaccination. However, tools for delivery of antigens to slanDCs were not available until now. Moreover, it is unknown whether
or not antigens delivered via the slan epitope can be taken up, properly processed and presented by slanDCs to T cells.
Methodology/Principal Findings: Single chain fragment variables were prepared from presently available decavalent
monoclonal anti-slan IgM antibodies but failed to bind to slanDCs. Therefore, a novel multivalent anti-slanDC scaffold was
developed which consists of two components: (i) a single chain bispecific recombinant diabody (scBsDb) that is directed on
the one hand to the slan epitope and on the other hand to a novel peptide epitope tag, and (ii) modular (antigen-containing)
linker peptides that are flanked at both their termini with at least one peptide epitope tag. Delivery of a Tetanus Toxin-derived
antigen to slanDCs via such a scBsDb/antigen scaffold allowed us to recall autologous Tetanus-specific memory T cells.
Conclusions/Significance: In summary our data show that (i) the slan epitope can be used for delivery of antigens to this
class of human-specific DCs, and (ii) antigens bound to the slan epitope can be taken up by slanDCs, processed and
presented to T cells. Consequently, our novel modular scaffold system may be useful for the development of human
vaccines.
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Introduction
B cells assemble a highly diverse repertoire of immunoglobulin
heavy and light chains by recombination of variable (V), diversity
(D), and joining (J) gene fragments, a process known as VDJ (heavy
chain) or VJ (light chain) recombination e. g. [1]. Upon antigen
encounter, antibody-encoding genes can undergo further modifi-
cations including somatic hypermutations (SHM) and class switch
recombinations (CSR). CSR replaces the m constant region (Cm) in
the heavy chain locus with one of the downstream constant regions
(Cc, Ce, Ca) leading to a switch from IgM type antibodies to
antibodies of the IgG, IgE or IgA type [1–7]. After CSR and
SHM, a positive selection favors the survival of those B cells which
express high affinity antibodies (‘‘affinity maturation’’). Conse-
quently, SHM and positive selection improve the affinity of the
paratope(s) of an antibody towards its epitope.
Human and mouse antibodies of the IgM type are pentameric
molecules containing ten paratopes. The binding avidity is the
result of multiple cooperative binding interactions with the
respective antigen. Most IgM antibodies have not undergone
affinity maturation. Therefore, monovalently binding recombinant
antibody fragments including for example single chain fragment
variables (scFvs) prepared from IgM type antibodies usually retain
only very low if any binding affinity e.g. [8].
In previous studies, the two IgM type monoclonal antibodies
(mabs) MDC8 and DD2 were established and characterised [9–
13]. Both mabs are directed to an O-linked carbohydrate
modification (6-sulfo LacNAc) on PSGL-1 that is selectively
expressed on a major population of myeloid derived human blood
dendritic cells (DC). This population, formerly termed M-DC8+
DC, was recently renamed as slanDCs [12]. SlanDCs are a major
population of proinflammatory human blood DCs, which mainly
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differ from other blood DC subsets by their selective phenotype (6-
sulfo LacNAc+ ( = slan+), CD1c2, CD11c+, CD142, CD16+,
CD45RA+, C5aR+) [9,11,12]. Functional data revealed that
slanDCs efficiently induce neoantigen-specific CD4+ T cells and
activate tumor-reactive CD8+ cytotoxic T cells (CTLs) [9,11]. In
addition, we found that slanDCs mediate antibody-dependent as
well as -independent tumor-directed cytotoxicity and promote
proliferation, IFN-c production, and tumoricidal potential of NK
cells [13].
Consequently, this subset of blood DCs represents a promising
target for in vivo delivery of antigens for vaccination [12]. As
mentioned above, all presently available anti-slanDC mabs (DD2
and MDC8) are IgM type antibodies. It is difficult to prepare a
therapeutic drug from IgMs for treatment of humans according to
the rules of good manufacturing practices (GMP) because one
cannot safely remove potentially contaminating virus particles
during purification. Here, we describe a novel modular multiva-
lent anti-slan scaffold for delivery of antigens to slanDCs.
Results
Strategy for the development of an in vivo targeting
system of slanDCs
In previous studies, we prepared and characterized the anti-slan
mab DD2 [9–13]. As schematically summarised in Figure 1(A) this
monoclonal IgM antibody has ten antigen binding sites. In a first
step we generated a scFv from the anti-slan mab DD2 (Fig. 1B,
DD2 scFv). In contrast to the polyvalent maternal IgM antibody,
the recombinant monovalent scFv failed to bind to slanDCs
(Fig. 1C, data not shown). We then tried to improve the affinity of
the anti-DD2 slan scFv by introducing random mutations. In spite
of a series of attempts, we were not able to isolate any DD2
derived mutant scFv which was capable to bind to slan DCs (data
not shown). As schematically summarised in Figure 1 (D to I), in
the next attempt we tried to partially restore the polyvalent anti-
DD2 platform by oligomerisation of monovalent recombinant
DD2 derived subunits: The idea was to create a scaffold consisting
of a scBsDb and suitable linker peptides (Fig. 1H,I). As source for
the scbsDb served two mabs including the anti-slan mab DD2
(Fig. 1D, DD2, S arm of the SL scBsDb) and a novel mab (Fig. 1E,
7B6, Bachmann unpublished; Fig. 1D, L arm of the SL scBsDb).
The mab 7B6 is directed to the aa sequence EKEALKKIIEDQ-
QESLNK which is part of the C-domain of a nuclear protein
known as La protein [14]. We abbreviated this continous aa
sequence as l-Tag. In addition to the SL scBsDb, linker peptide
molecules (Fig. 1F,G) were constructed containing the l-tag either
twice (Fig. 1F, l-GFP-l) or three times (Fig. 1G (i) l-l-GFP-l, (ii) l-
TTp-l-GFP-l). We hoped that the formation of bi- (Fig. 1H), tri-
(Fig. 1I), or other multivalent anti-slan scBsDb/linker peptide
scaffolds would allow us to sufficiently restore a binding to
slanDCs.
Until now it was also not known whether or not an antigen
bound to the slan epitope will be taken up and delivered to the
antigen presentation machinery of slanDCs. We, therefore,
wanted to learn, whether or not (i) an experimental antigen can
be delivered to slanDCs via such a scBsDb/linker peptide scaffold,
and (ii) will be taken up by slanDCs, processed and presented to T
cells. For this purpose, we planned to insert a common TT-derived
T-cell epitope (TTp) between the first and the second linker
epitope within the linker module l-l-GFP-l (Fig. 1G(ii)).
Construction and expression of the SL scBsDb
After amplification of the variable domains of the heavy and
light chains of both mabs (DD2,7B6) they were fused via glycine-
serine linkers as schematically shown in Figure 1D and Figure 2A.
The cloning, eukaryotic expression and purification of the SL
scBsDb is described in detail in Materials and Methods. Purified
SL scBsDbs were analysed by SDS-PAGE (Fig. 2C) and
immunoblotting (Fig. 2B). As shown in Figure 2 (B,C), the SL
scBsDb could be efficiently expressed and purified by Ni-NTA
affinity chromatography which is a prerequisite for a translation
into the clinic.
Construction and expression of multimeric linker
peptides
Linker peptide modules were cloned according to Figure 1 (F,G)
(see Materials and Methods), expressed in E. coli and purified. The
purified proteins were analysed by SDS-PAGE/immunoblotting
against the anti-La mab 7B6. As expected, the anti-La mab 7B6
reacted with the purified peptide linker proteins (Fig. 3) indicating
that the l-tag(s) are present and accessible for the 7B6 paratope.
Binding of the novel cell targeting system to the surface
of slan(+) Jurkat cells
During previous studies e.g. [11] we had observed that a
percentage of 5 to 10% of Jurkat cells are positive for the slan
epitope. These slan epitope positive (slan(+)) Jurkat cells can be
enriched by MACS (Materials and Methods) to a purity of more
than 95% and kept in culture (Fig. 4A(a)). For estimation of the
optimal formation and binding conditions of the complex, this
Jurkat cell line was used instead of slanDCs. In agreement with
previous data, the decavalent IgM anti-slan mab (DD2) is capable
of staining slan(+) Jurkat cells (Fig. 4A(a, red graph)). In contrast,
the monovalent anti-slan domain of the SL scBsDb fails to stain
slan(+) Jurkat cells (Fig. 4A(b, red graph)). However, binding was
regained when a multivalent anti-slan scaffold was formed by
preincubation of the SL scBsDb with either the l-GFP-l (Fig. 4A(c,
red graph)) or the l-l-GFP-l (Fig. 4A(d, red graph)) linker peptide.
Using epifluorescence microscopy, we could also detect the GFP-
labelled scBsDb/linker complexes on the surface of Jurkat cells
(Fig. 4B(a,b)).
In order to determine the optimal recovery conditions for
binding, increasing amounts of the SL scBsDb (50, 100, 150,
200 pmol/50 ml) were preincubated with the l-l-GFP-l linker
peptide (Fig. 5A) at molar ratios between 1 to 100 and 10 to 1. The
formed complexes were incubated with slan(+) Jurkat cells and the
binding was estimated by FACS analysis. Optimal bindings were
seen at concentrations of 100 to 200 pmol/50 ml of the scBsDb
(data not shown). The results for the combinations SL scBsDb
(150 pmol/50 ml) and l-l-GFP-l linker peptide are shown in
Figure 5 (A). The binding capability of the maternal IgM antibody
was set to 100%. The optimal binding ratios were between 2 to 1
and 1 to 2. Using the l-l-GFP-l linker peptide we were able to
recover between 78 and 95% of the maternal antibody binding
(Figs. 4(d);5A,B). Using the l-GFP-l linker peptide the efficiency
was less and ranged between 60 and 87% of the maternal antibody
(Figs. 4(c);5B). The binding of the SL scBsDb/linker peptide
scaffold depends on oligomerisation of the scBsDb via the linker
peptide as 2 to 4% of the maternal antibody binding was achieved
in the absence of a linker peptide (Fig. 4(b);5B, SL). Furthermore,
preincubation of the anti-slan(+) Jurkat cells with the anti-slan IgM
mab DD2 completely blocked the binding of the SL scBsDb/
linker peptide scaffold (Fig. 5B, DD2 IgM+SL+l-l-GFP-l).
In summary, our data show that monovalent recombinant
derivatives of the polyvalent anti-slan IgM mab DD2 are not
capable of binding to slanDCs. However, this loss of binding can
be restored by oligomerisation of monovalent anti-slan paratopes
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via the combination of SL scBsDbs with the peptide linker
modules that contain two or more l-Tag epitopes. For restoring of
the binding, a minimum of two anti-slan binding sites is required
although three binding sites are clearly superior.
Binding of the novel cell targeting system to the surface
of slanDCs
Next, we analysed the binding capability and specificity of the SL
scBsDb/linker peptide scaffold on human PBMCs (Fig. 6). As shown
in Fig. 6A (a) the presented PMBC sample contained about 1.4%
slanDCs, which is in a good agreement with previous estimations. As
shown in Fig. 6A (d), the trivalent anti-slan scaffold consisting of the SL
scBsDb and the l-l-GFP-l linker peptide allowed us to restore a specific
immuno targeting of slanDCs in PBMCs. The single components of
the scaffold system including the SL scBsDb (Fig. 6A(b)) and the l-l-
GFP-l linker peptide (Fig. 6A(c)) did not bind to slanDCs. The
presence of GFP in the linker module l-l-GFP-l allowed us to identify
the SL scBsDb/linker peptide complexes on slanDCs by epifluores-
cence microscopy (Fig. 6B(a,b)). Similar results were obtained for
PBMCs from three other human donors (data not shown).
Figure 1. Recombinant antibodies derived from IgM antibodies: Restoring avidity by oligomerisation on a modular peptide
scaffold. (A) The IgM anti-slan mab DD2 is a pentameric molecule. Preparation of a scFv (B) resulted in a monovalent molecule which failed to bind
to slanDCs (C, data not shown). For recovery of binding avidity a scBsDb (D, SL scBsDb) and suitable linking peptide molecules (F,G) were constructed
(H,I). In the scBsDb the variable heavy and light chain domains of the two mabs (A, DD2, S; E, 7B6, L) are recombinantly fused via glycine serine linkers
(D; see also Fig. 3). This SL scBsDb is on the one hand directed to the slan epitope and on the other hand to a continuous peptide epitope (l-Tag). The
linker peptide modules contain the l-Tag either two times (l-GFP-l, F) or three times (l-l-GFP-l, G(i); l-TTp-l-GFP-l, G(ii)). Binding of the SL scBsDb to the
respective linker peptides results in the formation of a divalent (H) or trivalent (I) anti-slan scaffold with increased avidity.
doi:10.1371/journal.pone.0016315.g001
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The presence of an experimental peptide antigen in a
linker molecule does not interfere with the formation
and binding of the multivalent anti-slan/linker peptide
complex to slan(+) Jurkat cells
In order to provide first evidence for proof of principle of the
novel immuno targeting strategy a known TT-derived T-cell
epitope region (Materials and Methods, TTp) was fused in between
the first and the second l-Tag of the l-l-GFP-l linker module (Fig. 1
G(ii)). As shown in Fig. 7(d, red graph) the complex formed
between the SL scBsDb and this l-TTp-l-GFP-l linker peptide is
capable of binding to slan(+) Jurkat cells. Moreover, the binding of
the antigen-containing linker peptide/SL scBsDb complex is
comparable to the binding of the l-l-GFP-l linker peptide/SL
Figure 2. Construction and characterisation of the SL scBsDb. (A) A schematic view of the structure and the complete AA sequence of the SL
scBsDb. (B) The SL scBsDb was expressed and purified as described under Materials and Methods. The flow through fractions, wash fractions (wash1,
wash2) and the eluted fractions (elution 1, elution 2) containing the SL scBsDb were analyzed by SDS-PAGE (C) and immunoblotting (B). After SDS-
PAGE separated protein(s) were stained with Coomassie brilliant blue (C, CBB), and after transfer the membrane was developed with an anti-penta-
HIS antibody (B). M, marker proteins.
doi:10.1371/journal.pone.0016315.g002
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scBsDb complex (Fig. 7c, red graph). None of the used single
components of the scaffold, including the SL scBsDb (Fig. 7(b,
black graph)) or the linker peptide containing or lacking the TT
derived peptide domain (Fig. 7(c,d, black graphs)), did bind on its
own to slan(+) Jurkat cells.
Consequently, the presence of the TT-epitope in the peptide
linker module does not interfere with the formation of the SL
scBsDb/linker peptide scaffold and its binding to slan(+) cells.
Stability of immune complexes present on the slan
epitope of isolated slanDCs
As described in Materials and Methods slanDCs can be isolated
from PBMCs. For this purpose PBMCs were preincubated with
the IgM anti-slan mab MDC8. SlanDCs were then isolated by
anti-IgM immuno magnetic beads. As a consequence, such
isolated slanDCs are covered with IgM anti-slan antibodies and
anti-IgM beads and, therefore, almost all slanDCs are also stained
by a FITC-labelled anti-IgM secondary antibody (Fig. 8A(a, black
graph)). Thus, an additional staining by IgM anti-slan abs DD2
only increases the MFI values (Fig. 8A(a, red graph). After an
incubation time of 4 h (Fig. 8A(b, black graph)) the FITC-
conjugated secondary anti-IgM antibody stains only 68% of the
slanDCs. This result indicates that the IgM abs and anti-IgM
beads used for the isolation have partially disappeared from the
surface of the slanDCs during this incubation time. This is also
supported by the finding that both number and MFI of these
slanDCs was increased when stained by the anti-slan IgM DD2 ab
and the FITC-labelled secondary anti-IgM ab (Fig. 8A(b, red
graph)). We interprete these data as follows: Anti-MDC8 IgM
mabs and/or anti-MDC8/anti-IgM beads used for isolation of
slanDCs are present on the surface of freshly isolated slanDCs and
block the binding of the anti-slan mab DD2. Over time the
MDC8/IgM immune complexes disappear from the surface and
additional unbound slan epitopes become available on the cell
surface which can then be stained by anti-slan (anti-DD2) abs. In
agreement with this interpretation, SL scBsDb/linker module
complexes also failed to bind on freshly isolated slanDCs (Fig. 8B(a,
black graph)). However, the binding of this multivalent anti-slan
scaffold consisting of the SL scBsDb and the l-TTp-l-GFP-l linker
module recovers after the 4 hr-incubation period at 37uC
(Fig. 8B(b, black graph)). After an additional incubation of 2.5 h
at 37uC, the SL scBsDb/linker peptide complexes also disappear
and can no more be detected on the surface of slanDCs (Fig. 8B(c,
black graph)).
Taken together, these results indicate that (i) immune complexes
bound to the slan epitope of PSGL-1 including immuno beads or
scBsDb/linker peptide complexes are either taken up by slanDCs
or released from the surface of slanDCs, and (ii) free ‘‘empty’’ slan
epitopes reappear on the surface of slanDCs.
Evidence for functional processing of the artificial
antigen-containing linker peptides
So far our data only showed that the novel immuno targeting
system can be used for the delivery of antigens to slanDCs in
PBMCs. It still had to be shown that (i) anti-slan bound antigens
can be taken up by slanDCs, and (ii) after uptake the antigens
delivered via PSGL-1 will be processed and presented on MHC
class II molecules to CD4+ T cells.
In case an antigen is taken up by a professional antigen
presenting cell (APC) it will be processed and the resulting peptides
will be presented on MHC class II molecules if fitting in the
binding groove of the respective MHC class II molecule. If a T-cell
epitope is obtained during cleavage and presented to memory
CD4+ T cells this should lead to a T-cell proliferation. Hence, in
the next step we wanted to show that T-cell epitopes when present
in our novel artificial linker module will be released during
processing and presented by APCs. As our l-TTp–l-GFP-l linker
peptide contains artificial TT-derived T-cell epitope(s) we looked
for healthy donors who were not only immunised with TT but
whose T cells were also able to respond to our selected TT-derived
peptide epitope.
The results for such a healthy donor are shown in Fig. 9 (A, (a to
d)). PBMCs of this donor when incubated for eight days at 37uC
with full length TT responded in a strong proliferation of CD4+ T
cells (about 28%, Fig. 9A(b)). As expected a CD8 response for TT
was very low (data not shown). In the absence of any recombinant
protein, the T cells did not respond after the same incubation time
(Fig. 9A(a)). Most of interest, CD4+ T cells responded with
proliferation when incubated with the l-TTp-l-GFP-l linker
peptide (Fig. 9A(d)), but did not respond to the corresponding
linker peptide l-l-GFP-l (Fig. 9A(c)) which only differs with respect
to the absence of the TTp sequence. Similar results were obtained
for PBMCs from three other human donors (data not shown).
These data indicate (i) the artificial antigen linker module can be
taken up by APCs in PBMCs, and (ii) be processed and thereby
TT-related T-cell epitope(s) are released and presented by MHC
class II molecules of the selected donor to CD4+ T cells resulting
in a proliferation in an antigen-specific manner. Furthermore, it
shows that the purified recombinant proteins are free of
contaminations such as lipopolysaccharides (LPS).
Induction of proliferation of T cells after delivery of a
TT-derived T cell epitope to slanDCs via the novel
immuno targeting system
Finally, we tried to show that our novel immuno targeting
system can indeed be used for the delivery of an antigen to
slanDCs in PBMCs and that this delivery can lead to an antigen
specific response of T cells. As slanDCs are not the only APCs in
PBMCs we developed the following strategy: From the presented
data we knew that (i) the l-TTp-l-GFP-l linker peptide can be taken
up at 37uC by APCs in PBMCs, (ii) but does not bind and is not
taken up by slanDCs or any other APC in PBMCs if incubated at
4uC, (iii) multivalent anti-slan scBsDb/linker peptide complexes
can be formed and specifically bind to slanDCs at 4uC but not to
the surface of other APCs present in PBMCs, and (iv) unbound
Figure 3. Characterisation of purified linker peptides. For the
formation of bi- or trivalent anti-slan scaffolds peptide linker molecules
were constructed containing the l-Tag twice (l-GFP-l) or three times (l-l-
GFP-l; l-TTp-l-GFP-l). The purified peptide linkers were analysed by SDS-
PAGE/immunoblotting using the anti-La mab 7B6 directed to the l-Tag.
(M) Marker proteins.
doi:10.1371/journal.pone.0016315.g003
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material can be removed by washing. Consequently, SL scBsDb/
linker module complexes formed and bound at 4uC on the surface
of slanDCs will not be removed by a washing step at 4uC while
unbound material will be removed. Therefore, unbound compo-
nents cannot be taken up by either other APCs present in PBMCs
or slanDCs. Only, scBsDb/linker module complexes will remain
and can eventually be taken up by slanDCs if the temperature is
raised to 37uC after washing. In the case that the immune
complexes formed on the surface of slanDCs will be eaten up by
APCs after raising the temperature to 37uC but not by slanDCs
then GFP fluorescence should be found within APCs others than
slanDCs.
Indeed, the specific delivery of the TTp T-cell epitope to
slanDCs via the SL scBsDb/l- TTp-l-GFP-l linker complex results
in a proliferation of the autologous CD4+ T cells (Fig. 9B(c)) while
the single components of the complex (Fig. 9B(a,b)) are unable to
induce proliferation. Similar results were obtained for PBMCs
from three independent human donors (data not shown).
Figure 5. Binding of the SL scBsDb/linker complex to slan(+) Jurkat cells. (A) Anti-slan scaffolds were obtained by incubation of the SL
scBsDb (SL) with the trivalent linker peptide l-l-GFP-l or the bivalent linker peptide (l-GFP-l, data not shown) at various ratios as indicated and
analyzed for binding to slan(+) Jurkat cells. Binding of the maternal IgM anti-slan antibody DD2 was set as 100%. (B) After estimation of the optimal
conditions, the binding of the bivalent (SL + l-GFP-l) and trivalent anti-slan scaffolds (SL+l-l-GFP-l) were compared to the binding of the maternal anti-
slan IgM antibody DD2 (DD2 IgM). Moreover, the binding of the scaffolds in the presence of the maternal anti-slan IgM antibody DD2 was determined
(DD2 IgM+SL+l-l-GFP-l).
doi:10.1371/journal.pone.0016315.g005
Figure 4. Analysis of binding of the SL ScBsDb/linker complex to DD2 positive Jurkat cells. (A), (a, black graph) IgM isotype negative
control. (a, red graph) Binding of the anti-slan IgM mab DD2 to slan(+) positive Jurkat cells. (b, black graph) Anti-penta-HIS, isotype negative control.
(b, red graph) Lack of binding of the monovalent SL scBsDb (SL) in the absence of a linker peptide. (c,d black graph) Isotype negative control. (c,d, red
graph) Bivalent or trivalent anti-slan scaffolds consisting of the SL scBsDb and the linker peptide l-GFP-l (c, red graph) or l-l-GFP-l (d, red graph). (B),
Detection of anti-slan scaffolds on the surface of Jurkat cells by epifluorescence microscopy. GFP (a), phase contrast (b), bar = 10 mm.
doi:10.1371/journal.pone.0016315.g004
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Moreover, GFP was never seen in any other cells from PBMCs
(data not shown).
Taken together, our data indicate that (i) the SL scBsDb can
form a multivalent anti-slan scaffold with peptide linker modules
that contain repetitive l-tags, (ii) T-cell epitopes can be inserted in
these artificial linker modules, (iii) insertion of peptide epitopes
does not affect the formation of the complex and the binding to
slanDCs, (iv) SL scBsDb/linker modules can be used for the
delivery of antigens to slanDCs, and (v) antigens bound to the slan
epitope can be taken up by these cells, processed and presented on
MHC class II molecules to T cells.
Discussion
Dendritic cells are key players in the immune system in that they
link the innate immune response to the adaptive immune response
[15]. Most of DCs in blood and peripheral tissues are immature.
In this state, they efficiently phagocytose antigens. Following
Figure 7. Immuno targeting of slan(+) Jurkat cells with a multivalent anti-slan scaffold containing a TT-derived T-cell epitope. (a,
black graph) Binding of the anti-slan mab DD2 to slan(+) Jurkat cells. (c,d, red graph) Binding of anti-slan scaffolds consisting of the SL scBsDb and
trivalent linker peptides either containing (c) or lacking (d) theTT-derived peptide epitope TTp. (b,c,d, black graph) Control binding of the single
components of the anti-slan scaffolds including the SL scBsDb (b), the trivalent linker l-l-GFP-l (c), and the trivalent linker l- TTp -l-GFP-l (d).
doi:10.1371/journal.pone.0016315.g007
Figure 6. Binding of the SL scBsDb/linker complex to native slanDCs in PBMCs. (A) (a) Estimation of the amount of slan-DCs in a PBMC
sample using the anti-slan IgM mab DD2. (d) Estimation of the amount of slanDCs in the same PBMC sample using the anti-slan scaffold consisting of
the SL scBsDb and the l-l-GFP-l linker peptide. Control staining of the single components of the anti-slan scaffold including the SL scBsDb (b, SL) or
the peptide linker module (c, l-l-GFP-l). (B) GFP-labelled anti-slan scaffolds identified by epifluorescence microscopy. GFP (a), phase contrast (b),
bar = 10 mm.
doi:10.1371/journal.pone.0016315.g006
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interaction with antigens and concomitant activating determi-
nants, DCs undergo a maturation process resulting in an
upregulated expression of adhesion, costimulatory, and MHC
molecules. Microbial products, including for example cell wall
components, non-methylated CpG DNA and double stranded
RNA have been identified as potent inducers of DC activation
[16]. Once mature, DCs are less phagocytic, and readily migrate
to the draining lymph nodes where they present the processed
antigens in the context of MHC to naı¨ve T cells leading to
activated effector CD4+ helper and CD8+ cytotoxic T cells. In the
conventional antigen presenting pathway, endogenously synthe-
sised proteins including viral proteins from virus-infected cells are
presented by MHC class I molecules. Antigens that are taken up
e.g. by phagocytosis are directed to lysosomes where they are
processed and then presented by MHC class II molecules. DCs
have an alternative pathway for class I presentation known as
‘‘cross-presentation’’, where cell-associated or soluble antigens
access and are presented by MHC class I molecules to CD8+ T
cells [17].
The progress in understanding the function of DCs has
stimulated much research on DC-based vaccination strategies
[18]. In the mouse model, the delivery of antigens via DCs was
successfully used for both initiation of antigenic tolerance and
initiation of immune responses, e.g., for reprogramming the
immune system against tumor cells [19,20–27].
Dendritic cell-based vaccines use autologous DCs that are either
generated in vitro from monocytes or isolated from patients. The
DCs are then loaded ex vivo with antigen prior to re-administration
to patients. Targeting DCs in vivo via specific surface receptors
represents a more direct and less laborious strategy.
Much was learned about in vivo targeting of DCs in mice.
Antigens were experimentally delivered to murine DCs in vitro or in
vivo via the DEC-205 receptor [20,28]. DEC-205 is a multilectin
receptor for adsorptive endocytosis that is expressed in mouse DCs
and some epithelia. For delivery of antigenic material to this
receptor, antigenic peptides are recombinantly fused to and
expressed as parts of an antibody to the DEC-205 receptor
[18,28–31]. This increases the efficiency of presentation of
antigens on both MHC class I and class II molecules in vivo
[20,21,30–32]. DEC-205 was also used for immuno targeting of
human DCs which were generated in vitro from monocytes of
healthy donors and malignant melanoma patients [33]. Targeting
of DCs may also be possible in humans as many types of human
DCs express more or less restricted marker molecules such as
langerin by Langerhans cells, DC-SIGN by dermal DCs, or
BDCA2 by pDCs.
As summarized in the introduction section, slanDCs represent a
major interesting subset of myeloid derived human blood DCs that
is capable of inducing neoantigen-specific CD4+ T cells as well as
tumor-reactive CD8+ CTLs [9,11]. Therefore, this subset of
human blood DCs represents an attractive candidate for an in vivo
delivery of antigens for vaccination including against tumor cells
[12].
SlanDCs can be stained in human PBMCs with the anti-slan
IgM mabs MDC8 and DD2 [9–13]. However, the slan epitope
does not exist on mouse DCs. In contrast to mouse DCs, slanDCs
are negative for the DEC-205 epitope (Bachmann, data not
shown). Consequently, human slanDCs cannot be targeted with
an anti-DEC-205 antibody. The use of anti-slan IgM mabs for
treatment of humans is also difficult because they cannot be
sufficiently purified and lose their binding capability when
monovalent derivatives are prepared (as shown herein). Moreover,
it was unclear whether or not antigens delivered to the slan
modification of PSGL-1 will be taken up by slanDCs, processed
and presented to T cells.
Therefore, we first tried to elicit high affinity IgG-type anti-slan
abs. However, in spite of a series of attempts we were not
successful to establish high affinity abs to the sulfated carbohydrate
structure representing the slan epitope. The final reason remains
unclear. One possible explanation could be that the PSGL-
backbone does not provide sufficient T cell help for class switch/
somatic hypermutation. In order to overcome this problem we
decided to develop a convenient modular cell targeting complex
for slanDCs. The idea was to multimerise recombinant monova-
lent antibody derivatives (scBsDbs) via suitable linker molecules
and, thereby, not only to restore the binding capability of the
polyvalent maternal IgM antibodies but also to deliver antigenic
peptides to slanDCs. Such antigen containing linker molecules can
easily be created by multiple tagging of the desired epitope
sequence(s) with the l-Tag. This procedure is much less laborious
and easier than fusion and recombinant expression of whole
antibody-antigen fusion proteins.
As shown in the result section we were indeed able to realise
such a versatile and modular scaffold: The novel immuno
targeting system allowed us to deliver a TT-derived T-cell epitope,
which was apparently taken up, processed and presented by
slanDCs resulting in the proliferation of CD4+ T cells. An uptake
of antigens via PSGL-1 is also supported by a recent publication of
Maugeri et al [34].
In our setting the proliferation of CD8+ T cells is hardly
measurable, including in the TT-positive control, therefore, we
presently don’t know whether or not the T-cell epitope taken up
via the slan epitope can also be cross-presented to CD8+ T cells.
For the formation of the scaffold we used in our studies linker
modules containing an antigen flanked by repetitive l-Tags. For a
clinical application the backbone flanking the antigen(s) should not
be antigenic or an immune response to the backbone should not
be critical. The l-Tag might fulfill these criteria: As mentioned
above the l-Tag represents an aa sequence which is present in the
C-terminal domain of the autoantigen La/SS-B. Twenty to thirty
percent of patients with systemic lupus erythematosus and up to
90% of patients with Sjo¨gren’s syndrome develop antibodies to this
nuclear antigen. Moreover, a varying percentage of about 5% of
healthy donors can also be found positive for the La antigen
[35,36]. Anti-La antibodies are assumed as epiphenomena in these
patients and even reported to be protective against anti-dsDNA
autoantibodies [35,36]. When we tested a series of anti-La positive
Figure 8. Stability of immune complexes formed via the slan epitope on isolated slanDCs. (A), (a, black graph) Staining of slanDCs freshly
isolated by magnetic anti-IgM/MDC8 anti-slan beads with a secondary FITC-conjugated anti-mouse IgM antibody. (a, red graph) Freshly isolated
slanDCs that are stained in addition with the anti-slan IgM mab DD2 and the secondary FITC-conjugated anti-mouse IgM antibody. (b, black graph)
Staining of slanDCs with a secondary FITC-conjugated anti-mouse IgM antibody four hrs after isolation and an incubation at 37uC. (b, red graph)
Staining of slanDCs with the anti-slan IgM mab DD2 and the secondary FITC-conjugated anti-mouse IgM antibody four hrs after isolation and an
incubation at 37uC. (B), (a, black graph) Binding of the multivalent anti-slan scaffold is blocked to freshly isolated slan DCs. (b, black graph) Binding of
the multivalent anti-slan scaffold consisting of the SL scBsDb (SL) and the l-TTp-l-GFP-l linker module regains four hrs after isolation and an incubation
at 37uC. (c, black graph) Staining of slan DCs after an additional incubation of 2.5 h at 37uC. The scBsDb/peptide linker scaffold can no more be
detected on the surface of slanDCs.
doi:10.1371/journal.pone.0016315.g008
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sera (n = 25) of autoimmune patients for reactivity to the 7B6
peptide epitope sequence representing the l-Tag none of the tested
anti-La positive autoimmune patient sera reacted with the 7B6
peptide epitope (data not shown). Consequently, an induction of
an immune response to the 7B6 peptide epitope in humans
appears unlikely as it does not even occur in autoimmune patients
developing an anti-La autoimmune response. And, if accidentally
induced, an anti-La response should not become life threatening as
anti-La antibodies are assumed to be non-pathogenic [35] and can
even occur in healthy individuals [36].
The novel modular cell targeting system is not limited to the
anti-slan IgM DD2. It should also be useful for introducing other
low affinity antibodies into therapy. By replacement of the anti-
slan specificity with another specificity, e.g., against a tumor-
associated antigen the scaffold system could be modified for either
drug delivery to tumor cells or redirecting of immune effector cells
to tumor cells or the improvement of tumor imaging.
In the future, even more sophisticated linkers could extend the
versatility of this novel immuno targeting system.
Materials and Methods
Ethics statement
Peripheral blood mononuclear cells (PBMCs) were isolated from
fresh blood by Ficoll-Hypaque density centrifugation as described
previously e. g. [11]. Alternatively, we used buffy coat cells which
were obtained from the transfusion blood center of the German
red cross. The materials were used with the informed written
consent of all participants. The study including the consent form
was approved by the local ethics committee of the university
hospital of the medical faculty of Carl-Gustav-Carus TU-Dresden
(EK27022006).
Preparation and expression of the novel SL scBsDb
For cloning of the SL scBsDb, the heavy and light chain
sequences of the two mabs DD2 and 7B6 were determined. For
this purpose, cDNAs were prepared from total RNAs that were
isolated from the respective hybridomas using TriPure reagent
(Roche, Mannheim, Germany) and the Advantage RT-for-PCR
Kit (Clontech/TaKaRa, Saint-Germain-en-Laye, France). The
respective cDNAs were amplified by PCR using the Advantage
HF 2 PCR Kit (Clontech/TaKaRa, Saint-Germain-en-Laye,
France) and primer pairs according to Wang et al. [37]. For
amplification of the heavy chain of the anti-slan mab DD2 we used
the primers HCfw2 (TT TTT GGA TCC SAR GTN MAG CTG
SAG SAG TCW GG) and IgM rev (ATT GGG ACT AGT TTC
TGC GAC AGC TGG ATT). The resulting PCR products were
subcloned into pGEM-T easy (Promega, Mannheim, Germany)
and sequenced. The pGEM-T clones were used as substrate for a
splicing by overlapping (SOE) PCR using the primers DD2_HC
SfiI fw (CCA TGG CGG ACT ACA AAG ATA TTG TGC TGA
CCC AGT CTC C), DD2_HC GS rev (CCA GAA CCA CCA
CCA CCA GAA CCA CCA CCA CCG GAT ACA GTT GGT
GCA GCA TC), DD2_LC GS fw (TGG TGG TTC TGG CGG
CGG CGG CTC CGG TGG TGG TGG ATC CGA AGT TAA
GCT GGA GGA G), and DD2_LC NotI rev (GCG GCC GCG
ACA TTT GGG AAG GAC TGA C) to construct the DD2 scFv
(Fig. 1B).
For construction of the bispecific DD2x7B6 scBsDb (SL
scBsDb, Figs. 1D, 2A), the 7B6 heavy chain was amplified with
the primers HC7B6scFv 1F (GGC GCC GGC GGC TCC GGT
GGT GGT GGT TCC GGT GGT GGT GGC TCC ATG
GCG GAC TAC AAA GAG GTC) and HC7B6scFv 2R (GGA
TCC ACC ACC ACC AGA GAC AGT GAC CAG AGT CCC
TTG GC). The 7B6 light chain was amplified with the primers
LC7B6scFv 1F (GGA TCC GAC ATT GTG CTC ACA CAG
TCT C), and LC7B6scFv 2R (GGC GCC AGA ACC ACC ACC
ACC AGA ACC ACC ACC ACC GGG CCC GGA TAC AGT
TGG TGC AGC ATC AGC). The light chain was cloned
upstream of the 7B6 heavy chain sequence using the artificially
created KasI restriction enzyme site in the linker sequence (all
restriction enzymes used were purchased from Fermentas, St.
Leon-Roth, Germany). This 7B6 light chain-heavy chain construct
was then cloned into the DD2 scFv sequence using BamHI
restriction enzyme sites resulting in the SL scBsDb reading frame.
For expression of the recombinant antibodies, all scFv reading
frames and also the reading frame of the SL scBsDb were
subcloned into the vectors pSEC-Tag2B and pcz CFG 5.1. For
this purpose artificial restriction enzyme sites (either SfiI and NotI
or EcoRI and Kpn2I) were introduced by PCR. The resulting
pSEC-Tag2B constructs were used for transient transfections of
HEK293T cells using Lipofectamine 2000 (Invitrogen, Karlsruhe,
Germany) according to the protocol of the manufacturer. The pcz
CFG 5.1 constructs were used to establish permanent cell lines by
transduction as described previously [38]. Recombinant scFvs or
scBsDbs were isolated from cell culture supernatants by affinity
chromatography using Ni-NTA agarose (Qiagen, Hilden,
Germany).
Construction of (antigen) linker peptides
Linker peptides suitable for (i) oligomerisation of the SL scBsDb,
and (ii) delivery of possible antigens to slanDCs, were cloned
containing the l-Tag either two times (Fig. 1F) or three times
(Fig. 1G(i) and (ii)). In all linker molecules, two of the l-Tag
epitopes were separated by green fluorescent protein (GFP) which
served as a marker and spacer molecule. An experimental antigen-
containing linker peptide was obtained by cloning a Tetanus
Toxin (TT) derived antigenic peptide (TTp) representing AA506–
526 (NYSLDKIIVDYNLQSKITLP) of TT between the first and
second l-Tag as schematically shown in Fig. 1G(ii). The different
linker modules were termed l-GFP-l (Fig. 1F), l-l-GFP-l (Fig. 1G(i)),
and l-TTp-l-GFP-l (Fig. 1G(ii)).
The cloning of the linker peptides was performed as follows:
The clone pET28b_La AA311–328 which encodes the minimal
7B6 aa epitope sequence served as template for PCR using the
primers LaEpitope_N(XhoI_AatII)_1F (59- CTC GAG AAA GAA
GCA CTG AAG AAA ATA ATA GAA GAC CAA CAA GAA
TCC CTA AAC AAA ACT AGG GAC GTC AGT ACT GAG
AAA GAA GCA CTG AAG -39) and pET28_SmaI_4R (CCC
GGG AAA ACA GCA TTC). The respective PCR fragment was
cloned into pET28b_La AA311–328 creating a novel clone with
two l-Tag sequences in a row separated by an artificial AatII
Figure 9. Analysis for proliferation of CD4+ T cells after delivery of the TT-derived T-cell epitope to slanDCs via the novel immuno
targeting system. (A) CFSE labeled PBMCs were prepared and incubated at 37uC for eight days with either full length TT (b) or the linker module
containing (d) or lacking (c) the TT-derived T-cell epitope TTp and analysed by FACS. The data indicate that PBMCs of the selected donor contain anti-
TT memory T cells that can be recalled by full length TT and to a less extent by the TTp peptide linker but not by the linker peptide lacking the TTp
epitope. Untreated PBMCs (a). (B) CFSE labelled PBMCs were incubated with either the antigen-containing scaffold (c) or the single components (a,b)
at 4uC. Unbound material was removed by washing.
doi:10.1371/journal.pone.0016315.g009
Immunotargeting of SlanDCs
PLoS ONE | www.plosone.org 13 January 2011 | Volume 6 | Issue 1 | e16315
restriction enzyme site. Herein, the EGFP reading frame sequence
was inserted. For cloning of the construct containing three l-Tag
elements, the pET28b_l-GFP-l DNA served as template for PCR
using the primers LaEpitope_N(Spe I)_2R (59- ACT AGT TTT
GTT TAG GGA TTC TTG TTG GTC TTC TAT TAT TTT
CTT CAG TGC TTC TTT CTC GCT AGC CAT ATG GCT
GCC GC -39) and pET28_Bgl II_1F (GAG GAT CGA GAT
CTC GAT C). Finally, this sequence was cloned into the
pET28b_l-GFP-l vector DNA resulting in the pET28b_l-l-GFP-l
plasmid DNA sequence. For delivery of the TT-derived antigenic
peptide TTp the AA sequence NYSLDKIIVDYNLQSKITLP was
inserted in between the first and second l-Tag element of the
pET28b_l-l-GFP-l plasmid. For this purpose pET28b_l-l-GFP-l
plasmid DNA was amplified by PCR using as primers the primer
TT506–525 (Hind III) R (59-AAG CTT CCT ACG AGG AAG
AGT AAT TTT AGA TTG AAG ATT ATA ATC AAC AAT
AAT TTT ATC AAG AGA ATA ATT TCG TCT CGG ATC
CCG ACC CAT TTG CTG) in combination with the primer
pET28 (Mlu I) 3F (59-AAT GAT CAG CCC ACT GAC GC).
The resulting construct was termed as the pET28b_l-TTP-l-GFP-l.
Plasmids encoding the respective linker peptide were transformed
into Escherichia coli (E. coli) BL21(DE3)pLysS bacteria (Merck-
Novagen, Nottingham, UK). Expressed recombinant proteins
were purified from bacterial extracts by Ni-NTA agarose affinity
chromatography under native conditions and analysed by SDS-
PAGE/immunoblotting. Detection was performed with either
anti-penta-HIS antibody (Qiagen, Hilden, Germany) or the anti-
La mab 7B6 and anti-mouse IgG conjugated with alkaline
phosphatase (Dianova, Hamburg, Germany).
Cell culture, FACS analysis and epifluorescence
microscopy
Commercially available Jurkat cells (ATCC TIB-152) were
grown in RPMI medium (Invitrogen, Karlsruhe, Germany)
containing 10% fetal calf serum (FCS, Biochrom, Berlin,
Germany). Slan(+) Jurkat cells represent a subpopulation present
in Jurkat cells (ATCC TIB-152): According to previous observa-
tions [11] about 5 to 10% of Jurkat cells express the slan
(previously termed MDC-8) epitope. Such slan(+) Jurkat cells can
be enriched from Jurkat cells using magnetic anti-IgM beads
(Miltenyi Biotech, Bergisch-Gladbach, Germany) coated with the
anti-slan mab MDC8 as described previously [11,13] (see also
Fig. 4A(a, red graph). SlanDCs were isolated from PBMCs using
the same approach.
For FACS analysis, slan(+) cells were stained with either the anti-
slan mab DD2 or the respective SL scBsDb/linker peptide complex.
The binding of single components of the respective SL scBsDb/
linker peptide complex was analysed in parallel. Briefly, cells were
incubated with 50 ml of hybridoma cell culture supernatant
containing the anti-slan mab DD2 and stained with a commercially
available PE-conjugated anti-IgM antibody (BD Biosciences/
Pharmingen, Heidelberg, Germany). For complex formation the
respective linker peptide was pre-incubated for 1 h at 4uC with the
SL scBsDb. Formed SL scBsDb/peptide linker complexes were
incubated for an additional 30 min to 1 h with either slan(+) Jurkat
cells, isolated slanDCs or PBMCs. Bound complexes were detected
with an Alexa488-labeled anti-penta-HIS mab (Qiagen, Hilden,
Germany). In the case of slanDCs, PE-conjugated anti-CD16 and
PE-Cy5-conjugated anti-HLA-DR were added to all samples. For
FACS analysis HLA-DR-positive monocytes were gated and slan(+)
cells were plotted versus CD16-positive cells. The amount of double
positive cells is the percentage of total cells. Data analysis was
performed using WinMDI 2.8 software.
Stained cells were documented by epifluorescence microscopy
using a Zeiss Axiovert 200 M epifluorescence microscope and the
Axio vision software package (release 4.6.3, Zeiss, Jena, Germany).
In the case that the GFP fluorescence present in the linker
modules was not sufficient for detection it was enhanced by
staining with an anti-GFP antibody covalently linked with FITC
(Acris Antibodies GmbH, Herford, Germany).
If not noted otherwise, all stainings were performed for 1 h at
4uC.
Proliferation assay
For the analysis of proliferation, isolated PBMCs were labelled
with carboxyfluorescein succinimidyl ester (CFSE) according to a
protocol described by Mannering et al. [39] using 0.5 mM CFSE in
PBS. Afterwards, cells were resuspended in medium and incubated
in the absence or presence of indicated proteins (16106 cells/well
in 2 ml medium in 24-well plates) for 8 days. TT (Behringwerke,
Marburg, Germany) was used at a concentration of 5 mg/ml,
linker peptides were used at a concentration of 350 nM.
Alternatively, 1.46106 cells/well were pre-incubated with recom-
binant proteins or pre-formed protein complexes (0.7 nmol l-TTp
-l-GFP-l linker peptide, 2.8 nmol SL scBsDb) for 1 h at 4uC in a
total volume of 400 ml in 24-well plates. Afterwards, cells were
washed twice with PBS to remove unbound proteins and pellets
were resuspended in 2 ml of medium. Medium used for culturing
of CFSE-labelled PBMCs consisted of RPMI 1640 (Biochrom,
Berlin, Germany) supplemented with 2 mM L-glutamine, 1 mM
sodium pyruvate, 1% (v/v) nonessential amino acids, 100 mg/ml
penicillin, 100 mg/ml streptomycin (all from Biochrom, Berlin,
Germany) and 10% (v/v) human serum (CC pro, Neustadt,
Germany).
Cells were cultured for 8 days and stained with PE-conjugated
anti-CD3 and PE-Cy5-conjugated anti-CD4 (BD Biosciences/
Pharmingen, Heidelberg, Germany) and analysed by flow
cytometry. CD3-positive cells were used to display CFSE versus
CD4 staining.
Acknowledgments
We thank Christine Gra¨fe, Heidrun Gebauer, Livia Schulze and Martina
Franke (Inst. Immunology, Carl Gustav Carus TU-Dresden, Gemany) and
Jody A. Gross (Oklahoma Medical Research Foundation, OK, U.S.A.) for
excellent technical assistance.
Author Contributions
Conceived and designed the experiments: MC HB MB. Performed the
experiments: CB AF SS MC AS SZ B-TK. Analyzed the data: CB AF SS
MC AS RW HB MB. Contributed reagents/materials/analysis tools: RW
MS AT KS E-PR R-HS MB. Wrote the paper: MB.
References
1. Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic
hypermutation. Annual Rev Biochem 76: 1–22.
2. Rajewsky K (1996) Clonal selection and learning in the antibody system. Nature
381: 751–758.
3. Stavnezer J (2000) Molecular processes that regulate class switching. Curr Top
Microbiol Immunol 245: 127–168.
4. Kinoshita K, Honjo T (2001) Linking class-switch recombination with somatic
hypermutation. Nat Rev Mol Cell Biol 2: 493–503.
5. Manis JP, Tian M, Alt FW (2002) Mechanism and control of class-switch
recombination. Trends Immunol 23: 31–39.
6. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, et al. (1999)
Specific expression of activation-induced cytidine deaminase (AID), a novel
Immunotargeting of SlanDCs
PLoS ONE | www.plosone.org 14 January 2011 | Volume 6 | Issue 1 | e16315
member of the RNA-editing deaminase family in germinal center B cells. J Biol
Chem 25: 18470–18476.
7. Bransteitter R, Pham P, Scharff MD, Goodman MF (2002) Activation-induced
cytidine deaminase deaminates deoxycytidine on single-stranded DNA but
requires the action of RNase. Proc Natl Acad Sci U S A 100: 4102–4107.
8. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of
single domains. Nat Biotechnol 23: 1126–1136.
9. Scha¨kel K, Mayer E, Federle C, Schmitz M, Riethmu¨ller G, et al. (1998) A novel
dendritic cell population in human blood: one-step immunomagnetic isolation
by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes.
Eur J Immunol 28: 4084–4093.
10. Scha¨kel K, Poppe C, Mayer E, Federle C, Riethmu¨ller G, et al. (1999) M-DC8+
leukocytes—a novel human dendritic cell population. Pathobiology 67:
287–290.
11. Scha¨kel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, et al. (2002) 6-Sulfo
LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflamma-
tory type of human dendritic cells. Immunity 17: 289–301.
12. Scha¨kel K, von Kietzell M, Ha¨nsel A, Ebling A, et al. (2006) Human 6-sulfo
LacNAc-expressing dendritic cells are principal producers of early interleukin-12
and are controlled by erythrocytes. Immunity 24: 767–777.
13. Schmitz M, Zhao S, Deuse Y, Scha¨kel K, Wehner R, et al. (2005) Tumoricidal
potential of native blood dendritic cells: direct tumor cell killing and activation of
NK cell-mediated cytotoxicity. J Immunol 174: 4127–4134.
14. Carmo-Fonseca M, Pfeifer K, Schro¨der HC, Vaz MF, Fonseca JE, et al. (1989)
Identification of La ribonucleoproteins as a component of interchromatin
granules. Exp Cell Res 185: 73–85.
15. Moll H (2003) Dendritic cells and host resistance to infection. Cell Microbiol 5:
493–500.
16. Sousa CRE, Sher A, Kaye P (1999) The role of dendritic cells in the induction
and regulation of immunity to microbial infection. Curr Opin Immunol 11:
392–399.
17. Wilson NS, Villadangos JA (2005) Regulation of antigen presentation and cross-
presentation in the dendritic cell network: facts, hypothesis, and immunological
implications. Adv Immunol 86: 241–305.
18. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against
cancer. Nat Rev Immunol 5: 296–306.
19. Proudfoot O, Apostolopoulos V, Pietersz GA (2007) Receptor-mediated delivery
of antigens to dendritic cells: anticancer applications. Mol Pharm 4: 58–72.
20. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002)
Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in
the steady state leads to antigen presentation on major histocompatibility
complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196:
1627–1638.
21. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. (2004)
In vivo targeting of antigens to maturing dendritic cells via the DEC-205
receptor improves T cell vaccination. J Exp Med 199: 815–824.
22. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells.
Annu Rev Immunol 21: 685–711.
23. Charalambous A, Oks M, Nchinda G, Yamazaki S, Steinman RM (2006)
Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong
CD4+ T cell immunity to mouse survivin. J Immunol 177: 8410–8421.
24. Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, et al.
(2007) DEC-205 receptor on dendritic cells mediates presentation of HIV gag
protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl
Acad Sci U S A 104: 1289–1294.
25. Do Y, Park CG, Kang YS, Park SH, Lynch RM, et al. (2008) Broad T cell
immunity to the LcrV virulence protein is induced by targeted delivery to DEC-
205/CD205-positive mouse dendritic cells. Eur J Immunol 38: 20–29.
26. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, et al. (2008) Targeting
the nuclear antigen 1 of Epstein Barr virus to the human endocytic receptor
DEC-205 stimulates protective T-cell responses. Blood 112: 1231–1239.
27. Mukhopadhaya A, Hanafusa T, Jarchum I, ChenYG, Iwai Y, et al. (2008)
Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion
and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad
Sci U S A 105: 6374–6379.
28. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, et al. (2000) The dendritic
cell receptor for endocytosis, DEC-205, can recycle and enhance antigen
presentation via major histocompatibility complex class II-positive lysosomal
compartments. J Cell Biol 151: 673–684.
29. Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, et al. (2005) On
the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells
prevents autoimmune diabetes. Diabetes 54: 3395–3401.
30. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells
induce peripheral T cell unresponsiveness under steady state conditions in vivo.
J Exp Med 194: 769–779.
31. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC (2004)
Immunological unresponsiveness characterized by increased expression of CD5
on peripheral T cells induced by dendritic cells in vivo. Immunity 20: 695–705.
32. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C,
et al. (2007) Differential antigen processing by dendritic cell subsets in vivo.
Science 31: 107–111.
33. Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, et al. (2010) Targeting of
DEC-205 on human dendritic cells results in efficient MHC class II-restricted
antigen presentation. Blood [Epub ahead of print].
34. Maugeri N, Rovere-Querini P, Evangelista V, Covino C, Capobianco A, et al.
(2009) Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine,
P-selectin, and b2 integrin-dependent cell clearance program. Blood 21:
5254–5265.
35. Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, et al. (2007)
Presence of anti-La autoantibody is associated with a lower risk of nephritis and
seizures in lupus patients. Lupus 16: 863–866.
36. Gaither KK, Fox OF, Yamagata H, Mamula MJ, et al. (1987) Implications of
anti-Ro/Sjo¨gren’s syndrome A antigen autoantibody in normal sera for
autoimmunity. J Clin Invest 79: 841–846.
37. Wang Z, Raifu M, Howard M, Smith L, Hansen D, et al. (2000) Universal PCR
amplification of mouse immunoglobulin gene variable regions: the design of
degenerate primers and an assessment of the effect of DNA polymerase 39 to 59
exonuclease activity. J Immunol Methods 13: 167–177.
38. Morgenroth A, Cartellieri M, Schmitz M, Gu¨nes S, Weigle B, et al. (2007)
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using
genetically engineered T-cells. Prostate 67: 1121–1131.
39. Mannering SI, Morris JS, Jensen KP, Purcell AW, Honeyman MC, et al. (2003)
A sensitive method for detecting proliferation of rare autoantigen-specific human
T cells. J Immunol Methods 283: 173–183.
Immunotargeting of SlanDCs
PLoS ONE | www.plosone.org 15 January 2011 | Volume 6 | Issue 1 | e16315
